CrossrefInfokarte
Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
ClinicoEconomics and Outcomes Research · 2023-09 · Volume 15 · 659-671
DOI: 10.2147/ceor.s415711 ↗Abstract
Kein Abstract verfügbar.
EUVIMED